Leerink raised the firm’s price target on Wave Life Sciences to $20 from $16 and keeps an Outperform rating on the shares. The firm believes Wave Life’s previously underappreciated Duchenne muscular dystrophy candidate, WVE-N531, can be significantly differentiated versus approved skippers based on an improved dosing schedule, cleaner safety, and more comprehensive efficacy that could translate to functional improvements. Such improvements further validate the company’s PRISM platform and increases Leerink’s excitement for the company’s additional programs, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Deere dips after Trump tariff threat, DOJ to sue Visa: Morning Buzz
- Wave Life Sciences price target raised to $22 from $15 at H.C. Wainwright
- Wave Life Sciences Reports Promising Duchenne Therapy Trial Results
- Wave Life Sciences announces interim data fom ogoing Phase 2 FORWARD-53 study
- Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping